Peter S Hall

Summary

Affiliation: University of Leeds
Country: UK

Publications

  1. doi request reprint Expected net present value of sample information: from burden to investment
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Med Decis Making 32:E11-21. 2012
  2. doi request reprint Current perspective - trastuzumab
    Peter S Hall
    University of Leeds, UK
    Eur J Cancer 45:12-8. 2009
  3. doi request reprint Health economics in drug development: efficient research to inform healthcare funding decisions
    Peter S Hall
    University of Leeds, Charles Thackrah Building, 101 Clarendon Road, Leeds LS2 9LJ, UK
    Eur J Cancer 46:2674-80. 2010
  4. doi request reprint Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Pharmacoeconomics 29:415-32. 2011
  5. doi request reprint Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, UK
    J Natl Cancer Inst 104:56-66. 2012

Detail Information

Publications6

  1. doi request reprint Expected net present value of sample information: from burden to investment
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Med Decis Making 32:E11-21. 2012
    ..The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy...
  2. doi request reprint Current perspective - trastuzumab
    Peter S Hall
    University of Leeds, UK
    Eur J Cancer 45:12-8. 2009
    ..This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer...
  3. doi request reprint Health economics in drug development: efficient research to inform healthcare funding decisions
    Peter S Hall
    University of Leeds, Charles Thackrah Building, 101 Clarendon Road, Leeds LS2 9LJ, UK
    Eur J Cancer 46:2674-80. 2010
    ..The potential for decision theoretic methods to help overcome these problems is introduced and potential obstacles in implementation are highlighted...
  4. doi request reprint Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
    Pharmacoeconomics 29:415-32. 2011
    ..We present an updated cost-effectiveness analysis from the UK perspective, which explores assumptions about the duration of benefit from treatment, pattern of metastatic recurrence and long-term cardiac toxicity...
  5. doi request reprint Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer
    Peter S Hall
    Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, UK
    J Natl Cancer Inst 104:56-66. 2012
    ..This economic evaluation compared genomic test-directed chemotherapy using the Oncotype DX 21-gene assay with chemotherapy for all eligible patients with lymph node-positive, estrogen receptor-positive early-stage breast cancer...